



## **Univ.-Prof. Dr. Gerd Assmann, FRCP**

**Chairman: 1995 – 2003**

**Executive Director: 2003 – 2014**



# International Task Force for Prevention of Cardiometabolic Diseases

## - a brief historical overview -

G. Assmann (chairman: 1995 to 2003, executive director: 2003 to 2014)  
D. Müller-Wieland (executive director: 2015-2020)

Foundation .....	3
Goals.....	3
Funding.....	4
Composition .....	4
Members .....	5
Current Board Members .....	5
Honorary members .....	5
Activities and publications (short version).....	6
Symposia .....	12

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



## Foundation

The concept of a task force first arose in response to the momentum created by the 1985 National Institutes of Health Consensus Statement and the 1986 European Atherosclerosis Society Policy Statement on coronary heart disease prevention. It was felt by many that there was a need for an international body to pool expertise in prevention from many countries.

This perception led to the formal constitution of the ***International Task Force for Prevention of Coronary Heart Disease Foundation*** at an inaugural meeting in Frankfurt on April 30, 1987, and to its official registration in Geneva as a non-profit foundation.

First chairman: Professor Barry **Lewis**.

Founder members: Gerd **Assmann**, Henry **Blackburn**, Rafael **Carmena**, Jean **Davignon**, Jean-Luc **de Gennes**, DeWitt S. **Goodman**, John **Goodwin**, Yuichiro **Goto**, Antonio **Gotto**, Markus **Hanefeld**, Robert **Hodge**, Claude **Lenfant**, Mario **Mancini**, Costas **Miras**, Paul **Nestel**, R. G. **Oganov**, Anders **Olsson**, Rodolfo **Paoletti**, Zbignek **Pisa**, Daniel **Pometta**, Kalevi **Pyörälä**, Gotthard **Schettler**, Yechezkiel **Stein**, Robert **Wissler**.

In 2012 the ***Task force*** was renamed as International Task Force for Prevention of Cardiometabolic Diseases.

## Goals

The aim of the ***Task Force*** is the diffusion at an international level of easily assimilable information on the prevention of coronary heart disease for physicians, medical professionals and the public.

The activities of the ***Task Force*** fall into three categories:

1. Promotion of the study of preventive strategies and preparation of expert reports and teaching materials. To assist in this activity, the ***Task Force*** maintains contacts with the media, governmental organizations, industry, health insurers and other interested parties.
2. The ***Task Force*** promotes the formulation of clear, simple and up to date guidelines for the prevention of cardiometabolic diseases based on current scientific evidence. Wherever possible, it works through national and local organizations for the diffusion of these guidelines.
3. The holding of small, high-level conferences on particular aspects of preventive strategy requiring updating or clarification, and the rapid publication and dissemination of the proceedings of these symposia.

The founders of the ***Task Force*** made a conscious decision not to include research activities in its terms of reference. Numerous societies focus on research into heart disease. The ***Task Force*** however is a specialized international organization with the primary goal of translating into practice the large body of knowledge now available on the causes and prevention of cardiometabolic diseases. In many parts of the world, particularly in Asia, the incidence of vascular disease is increasing sharply, so that for the first time in the history of humanity vascular disease has now supplanted infectious disease as the number one killer worldwide.

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



## Funding

The **Task Force** is funded by donations and legacies, by profits arising from the sale of scientific documents, and by sponsoring and registration fees of its seminars and symposia. All office holders of the **Task Force** are unpaid.

## Composition

The **Task Force** is composed of experts of various nationalities who are holders of or have recently retired from senior academic posts. All have extensive research experience in relevant medical specialities. Many members provide cross-representation with other international bodies and cardiology societies. The **Board** of the **Task Force** is composed as follows:

- Up to 31 voting members elected by co-optation among persons having the qualities, experience and professional skills in the field of coronary heart disease required for the good working and the effectiveness of the foundation.
- An unlimited number of non-voting advisory or honorary members

The Board appoints from among its members an **executive committee** of no more than nine members. 2019 currently composed of a **Chairman** (Eduardo Farinaro, Italy), a **Vice-Chairman** (Heiner Greten, Germany), a **Treasurer** (Walter Riesen, Switzerland), an **Executive Director** (Dirk Müller-Wieland, Germany), and **Members** (Gerd Assmann, Rafael Carmena, Matti Tikkanen, Arnold Von Eckardstein, Abders Olsson).



## Members

### Current Board Members

- Gerd Assmann
- Virgil Brown
- Rafael Carmena
- Eduardo Farinaro
- Jean-Charles Fruchart
- Antonio Gotto
- Heiner Greten
- Dirk Müller-Wieland
- Anders Olsson
- Walter Riesen
- Evgeny Shlyakhto
- Matti Tikkanen
- Arnold von Eckardstein
- Nikolaus Marx
- Barry Goldstein
- Maurizio Trevisano

### Honorary members

- Barry Lewis
- Mario Mancini

### Previous Board Members

- Philip Barter
- Bryan Brewer
- Alberico Catapano
- Jean Davignon
- Jean-Pierre Després
- Michel Farnier
- Scott Grundy
- Anders Hamsten
- John Kastelein
- Eran Leitersdorf
- Yuji Matsuzawa
- Marek Naruszewicz
- Rodolfo Paoletti
- Terje Pedersen
- Marja-Riitta Taskinen
- Matti Tikkanen



## Activities and publications (short version)

- 1988      1. **"Handbook of Coronary Heart Disease Prevention - a practical guide"**  
Distributed in Europe, free of charge and in several languages
- 1989      2. **"The social and economic contexts of coronary prevention"**  
Proceedings of a meeting held by the Int. Task Force for Prevention of Coronary  
Heart Disease  
Linköping, Sweden, 16.08.1989
- 1992      3. **"Prevention of coronary heart disease. Scientific background and new clinical  
guidelines"**  
Recommendations of the European Atherosclerosis Society (EAS) prepared by the  
*Task Force*  
*Current Medical Literature Ltd*, London  
*Nutr Metab Cardiovas Dis* (1992), Vol. 2, No. 3, pp. 113-156
- 1993      4. **"Low blood cholesterol: Health implications"**  
Proceedings of a workshop held in Milan, July 1993, under the auspices of the *Task  
Force* and the International Society and Federation of Cardiology. Eds. Lewis,  
Paoletti, Tikkanen  
*Current Medical Literature Ltd.*, London
- 1994      5. **"Desktop guide to the management of risk factors for coronary heart disease"**  
Summary of the EAS recommendations "Prevention of coronary heart disease –  
scientific background and new clinical guidelines".  
This was translated into 10 languages and distributed to 500,000 physicians  
worldwide
- 1997      6. **"Treatment goals for low-density lipoprotein cholesterol in the secondary  
prevention of coronary heart disease: absolute levels or extent of lowering?"**  
Proceedings of a symposium of the *Task Force* and the Institute of Arteriosclerosis  
Research at the University of Münster, held in Berlin, October 1996  
*Am J Cardiol* 1997; 80:1287-1294



- 1998
7. „Coronary heart disease: Reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view“  
*Nutr Metab Cardiovas Dis* (1998) 8:205-271  
<http://www.chd-taskforce.com/guidelines>  
  
Published also as short scientific version in  
*Arterioscler Thromb Vasc Biol.* (1999;19:1819-1824), and as abbreviated version in  
*Circulation*, (1999;100:1930-1938)
  8. “Primär- und Sekundärprophylaxe der koronaren Herzkrankheit (KHK). Neueste internationale Empfehlungen“  
G. Assmann, Review  
*Notabene medici* 12; 610-611, 1998
- 1999
9. Establishing and refining the *Task Force* website: [www.chd-taskforce.com](http://www.chd-taskforce.com). This contains links to the PROCAM study, an interactive risk calculator and also a series of slide kits on issues of coronary heart disease prevention.
  10. “Nutrition and longevity: Optimal diet in industrialized countries”  
Proceedings of the *Task Force* meeting held in Capri, June 1998  
*Nutr Metab Cardiovas Dis* (1999) 9, Suppl to No. 4  
<http://www.chd-taskforce.com/oliveoil>
  11. “Update on the latest findings on secondary prevention of coronary heart disease” Press conference, Naples, February 1999
  12. “Coronary Heart Disease: Reducing the risk – A worldwide view”  
*Circulation*. 100: 1930-1938, 1999
  13. „Coronary heart disease: Reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view“  
*Arterioscler Thromb Vasc Biol.* 19: 1819-1824, 1999
  14. “Coronary heart disease prevention task force” – Letters to the editor  
*European Heart Journal*. 20: 841-844, 1999

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide



- 2000
15. **“Primary prevention of coronary heart disease. From controversy to consensus”**  
Proceedings of the *Task Force* meeting held in Paris, May, 1999.  
*Nutr Metab Cardiovas Dis* (2000) 10:143-153
  16. **“Prevention of coronary heart disease in post-menopausal women”**  
Proceedings of the *Task Force* Meeting in Scuol, Dec. 1999.  
*Nutr Metab Cardiovas Dis* (2000) 10:267-274  
<http://www.chd-taskforce.com/practicalaid.htm>
  17. **“2000 Consensus Statement: dietary fat, the mediterranean diet, and lifelong good health”**  
Summary of the 2000 International Conference on the Mediterranean Diet, held in London, January 2000  
[http://www.chd-taskforce.com/2000consensusstatement/index\\_e.htm](http://www.chd-taskforce.com/2000consensusstatement/index_e.htm)
  18. **“Primäre und sekundäre Prävention der koronaren Herzkrankheit”**  
Statement of the *Task Force*  
*Dtsch.med.Wschr.* (2000) 125: 881-887
  19. **“Consensus on Statins”** (Japan)  
Prous Science 2000
- 2001
20. **“Consensus on statins”**  
*Task Force* meeting held in Paris, September 2000  
Internet presentation of slides: <http://www.chd-taskforce.com/statins2000>
  21. **“Obesity and cardiovascular risk”**  
*Task Force* meeting held in Valencia, June 2000  
*Nutr Metab Cardiovas Dis* (2001) Vol. 11
  22. **“Subclinical atherosclerosis - the presymptomatic patient at risk for myocardial infarction and stroke”**  
*Task Force* meeting held in New York, September 2001  
Internet presentation of slides: <http://www.chd-taskforce.com/newyork2001.htm>
  23. **“Hypolipidemic Treatment in Children and Young Adults”**  
Proceedings of the *Task Force* workshop held in Anacapri, May 2001  
*Nutr Metab Cardiovas Dis*, Volume 11, Suppl. to No. 5, October 2001
  24. **“Statement of the International Task Force for Prevention of Coronary Heart Disease on the use of statins”**  
[www.chd-taskforce.de/statin\\_statement](http://www.chd-taskforce.de/statin_statement)
  25. **“Das Herz soft schützen”**  
Vital, Oktober 2001





- 2002      26. **“Eat and live heart-healthy”**  
A comprehensive internet-practical on modifying nutritional habits and life-style, aimed at patients who are at high risk of coronary heart disease and members of the health-care professions. Available in the English and the German language.  
<http://www.chd-taskforce.com/heart-healthy>  
<http://www.chd-taskforce.com/herzgesund>
27. **“Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study**  
Circulation. 105: 310-315, 2002
- 2002-2004      28. **Scientific News: Regarding Observational Studies, Interventional Studies, Selected reviews, Current Guidelines (since 1995), Landmark trials**  
extensive literature research – some articles are provided with commentaries by the Task Force experts
- 2003      29. **“Combined use of multi-slice CT and the PROCAM calculator for stratification of risk of coronary heart disease”**  
A consensus statement on behalf of the Task Force
30. **“Pocket guide to prevention of coronary heart disease”**  
Prepared by the *Task Force* in cooperation with the International Atherosclerosis Society  
Worldwide distribution by local organizations  
*Translations are available in: German, Dutch, Polish, French, Spanish, Italian,*
31. **„Prävention der koronaren Herzkrankheit“**  
*Dade Behring News 3: 14-22, 2003*
32. Design and distribution of the **“Prevention Card”** (“Principles of prevention of cardiovascular disease”) in the English and the German language, for distribution to physicians.  
A joint *Task Force* / IAS project
33. **“Consensus on the management of dyslipidemias”** (Consensus on Statins update) (Japan)  
Prous Science 2003



- 2004
34. **“Cholesterol-lowering with statins: are they all the same?”**  
Summary of the Expert Symposium at the 53<sup>rd</sup> Annual Scientific Sessions of the American College of Cardiology, New Orleans, March 2004  
*Drugs of Today* 2004, 40(6):555-561
35. **“Treatment guidelines for dyslipidemia”**  
Expert Panel Meeting and position paper, June 2004  
see internet pages
36. **“Implications of emerging risk factors for therapeutic intervention”**  
An Expert Panel report, Munich 27, 2004  
(also published in *Nutrition, Metabolism & Cardiovascular Diseases* (2005), 15,373-381
37. **“New perspectives: CV risk assessment including non-invasive CT”**  
Expert Panel Meeting and press conference, Munich, August 2004
- 2005
38. **1<sup>st</sup> Meeting of the Latin American Task Force**  
Santiago de Chile, January 2005
39. **“Das Risiko für Herzinfarkt besser erkennen und effektiver senken – neue Erkenntnisse aus der internationalen Forschung”**  
Press conference, Hamburg, March 2005
40. **„Cholesterol, Alzheimer´s and statins“**  
Symposium of the *Task Force*, Stockholm, April 2005
41. **3<sup>rd</sup> Regional meeting on prevention of CHD and stroke**  
Beirut, September 2005
42. **“Implications of emerging risk factors for therapeutic intervention”**  
*Nutrition, Metabolism & Cardiovascular Diseases* 15, 373-381, 2005
- 2006
43. **3<sup>rd</sup> Metabolic syndrome, type II diabetes and atherosclerosis congress,**  
Marrakesh, May 2006
44. **XIV International Symposium on Atherosclerosis (ISA)**  
Rome, June 2006  
Scientific sponsorship
45. **“Erectile dysfunction and the cardiovascular patient”**  
Task Force Meeting, Helsinki, September 2006



- 2007      46. **Erectile dysfunction as a risk factor for CHD: implications for prevention**  
Review Article  
*Int. J. Clin. Pract.*, February 2007, 61;2,265-268
47. **Assessing risk of myocardial infarction and stroke: new data from the  
Prospective Cardiovascular Münster (PROCAM) study**  
G. Assmann, H. Schulte, P. Cullen, and U. Seedorf  
*Eur. J. Clin. Invest.* December 2007, 37; 12,915-1010
- 2008 to    48. **“Pocket guide to prevention of coronary heart disease”**  
2011      Prepared by the *Task Force* in cooperation with the International Atherosclerosis  
Society  
Worldwide distribution by local organizations  
**Translations are available in:**
- *English (published 2009, 30.000 copies)*
  - *Spanish (published 2008, 15.000 copies)*
  - *German (published 2009, 15.000 copies)*
  - *Italian (published 2009, 15.000 copies)*
  - *French (published 2011)*
  - *Russian (published 2011, 30.000 copies)*
- 2014      49. **Functional foods and cardiometabolic diseases. International Task Force for  
Prevention of Cardiometabolic Diseases.**  
G. Assmann, P. Buono, A. Daniele, E. Delle Valle, E. Farinaro, G. Ferns, V. Krogh, D.  
Kromhout, L. Masana, J. Merino, G. Misciagna, S. Panico, G. Riccardi, A.A.  
Rivellese, R. Rozza, F. Salvatore, V. Salvatore, S. Stranges, M. Trevisan, B. Trimarco,  
C. Vetrani. *Nutr Metab Cardiovasc Dis* 2014; 24: 1272-1300.
- 2016      50. **Treat-to-Target versus Dose-Adapted Statin Treatment of Blood Cholesterol to  
Reduce Atherosclerotic Cardiovascular Risk in Adults — Position Statement  
of the International Task Force for the Prevention of Cardiometabolic Diseases**  
D. Müller-Wieland, G. Assmann, R. Carmena, J. Davignon, A. von Eckardstein, E.  
Farinaro, H. Greten, A.G. Olsson, W.F. Riesen, E. Shlyakhto  
*Eur J Prev Cardiol* 2016; 23: 275-81
- 2017      51. **Can LDL cholesterol be too low? Possible risks of extremely low levels.**  
A.G. Olsson, B. Angelin, G. Assmann, C.J. Binder, I. Björkhem, A. Cedazo-Minguez,  
J. Cohen, A. von Eckardstein, E. Farinaro, D. Müller-Wieland, K.G. Parhofer, P.  
Parini, R.S. Rosenson, J. Starup-Linde, M.J. Tikkanen, L. Yvan-Charvet.  
*J Intern Med* 2017; 281: 534-553 *Eur J Prev Cardiol* 2016; 23: 275-81



## Symposia

organized or co-sponsored (scientific sponsorship) by the *Task Force*:

- |                |  |
|----------------|--|
| August 1989    | 1. <b>Social and economic contexts of coronary prevention – including financial costs and savings and demographic effects</b><br>Linköping, Sweden               |
| June 1992      | 2. <b>Coronary disease prevention in the elderly</b><br>Florence, Italy  |
| July 1993      | 3. <b>Health implications of low blood cholesterol - are there dangers as well as benefits in lowering blood cholesterol?</b><br>Milan, Italy                    |
| May 1995       | 4. <b>Genetics of lipoprotein metabolism disorders and atherosclerosis</b><br>Münster, Germany   |
| October 1995   | 5. <b>Aging and cardiovascular diseases</b><br>Münster, Germany  |
| December 1995  | 6. <b>Menopause and cardiovascular diseases</b><br>Rome, Italy   |
| March 1996     | 7. <b>Health risks of smoking</b><br>Münster, Germany  |
| March 1996     | 8. <b>Assessment of the risk of cardiovascular disease – Medical and insurance perspectives</b><br>London, UK  |
| September 1996 | 9. <b>Cholesterol and brain metabolism</b><br>Anacapri, Italy  |
| October 1996   | 10. <b>Treatment goals for LDL Cholesterol in the secondary prevention of coronary heart disease: Absolute levels or percentage lowering?</b><br>Berlin, Germany |
| April 1997     | 11. <b>Hypertriglyceridemia, the metabolic syndrome, and coronary heart disease risk</b><br>Madrid, Spain  |
| July 1997      | 12. <b>Dyslipidemia and endothelial dysfunction</b><br>Dresden, Germany  |

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



- |                |  |
|----------------|--|
| June 1998      | 13. <b>Nutrition and longevity</b><br>Capri, Italy   |
| October 1998   | 14. <b>Atherothrombosis and Triglycerides</b><br>Paris, France   |
| May 1999       | 15. <b>Primary prevention of coronary heart disease – from controversies to consensus</b><br>Paris, France                             |
| December 1999  | 16. <b>Prevention of coronary heart disease in post-menopausal women</b><br>Scuol, Switzerland   |
| January 2000   | 17. <b>2000 International Conference on the Mediterranean Diet</b><br>London, UK   |
| June 2000      | 18. <b>Obesity and coronary heart risk</b><br>Valencia, Spain  |
| September 2000 | 19. <b>Consensus on statins</b><br>Paris, France   |
| October 2000   | 20. <b>AMAD – Actualización en el manejo de las dislipidemias</b><br>Meeting of Latin American Experts<br>Münster, Germany             |
| May 2001       | 21. <b>Hypolipidemic treatment in children and young adults</b><br>Anacapri, Italy   |
| September 2001 | 22. <b>Subclinical atherosclerosis – the presymptomatic patient at high risk for myocardial infarction and stroke</b><br>New York, USA |
| October 2001   | 23. <b>Premières Journées Francophones de Prevention Cardio-Vasculaire</b><br>Beirut, Lebanon (planned, but cancelled)                 |
| March 2002     | 24. <b>Metabolic Syndrome and Atherosclerosis</b><br>Lille, France   |
| June 2002      | 25. <b>6<sup>th</sup> International Symposium on Global Risk of Coronary Heart Disease and Stroke</b><br>Florence, Italy               |

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



- |                |   |
|----------------|---|
| October 2002   | 26. <b>The 4<sup>th</sup> Krag Atherothrombosis Conference</b><br>Krag Castle, Poland   |
| February 2003  | 27. <b>Identifying sub-clinical atherosclerotic disease: An evaluation of emerging techniques</b><br>Scuol, Switzerland   |
| April 2003     | 28. <b>2003 Consensus on the management of dyslipidemias</b><br>Paris, France   |
| May 2003       | 29. <b>Presentación prevención de la Enfermedad Coronaria</b><br>Barcelona, Spain   |
| October 2003   | 30. <b>Experts meeting on prevention and the new prevention laws</b><br>Münster, Germany  |
| March 2004     | 31. <b>Are all statins the same?</b><br>Expert meeting, New Orleans, USA  |
| May 2004       | 32. <b>2<sup>nd</sup> Metabolic syndrome and atherosclerosis congress</b><br>Marrakech, Marocco   |
| August 2004    | 33. <b>New Perspectives: Cardiovascular risk assessment including non-invasive computed tomography</b><br>Munich, Germany   |
| April 2005     | 34. <b>Conference on Cholesterol, Alzheimer's Disease and Statins</b><br>Stockholm, Sweden  |
| September 2005 | 35. <b>Second Middle East CARDIOPACE – from pill to wire and devices</b><br>The 3 <sup>rd</sup> Regional meeting on prevention of coronary heart disease and stroke,<br>Beirut, Lebanon |
| May 2006       | 36. <b>3<sup>rd</sup> Metabolic syndrome, type II diabetes and atherosclerosis congress</b><br>Marrakesh, Marocco   |
| June 2006      | 37. <b>XIV International Symposium on Atherosclerosis (ISA)</b><br>Rome, Italy  |
| September 2006 | 38. <b>2<sup>nd</sup> German Atherosclerosis Congress</b><br>Münster, Germany   |

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



- September 2006    39. **Erectile dysfunction and the cardiovascular patient**  
Helsinki, Finland
- May 2007    40. **4<sup>th</sup> Metabolic syndrome, type II diabetes and atherosclerosis congress**  
Lisbon, Portugal
- May 2007    41. **Task Force Symposium – Scientific session “Risk stratification in CHD prevention: emerging new risk factors”**  
Valencia, Italy
- May 2007    42. **1<sup>st</sup> Workshop on “Cardiovascular risk factors management”**  
Prag, Czech Republic
- June 2007    43. **2<sup>nd</sup> International Symposium “Intergrated Biomarkers in Cardiovascular Diseases”**  
Berlin, Germany  
**Scientific sponsorship**
- October 2007    44. **Middle East Chapter “Workshop on management of risk factors”**  
Amman, Jordan
- October 2007    45. **XVI International Symposium on “Drugs affecting Lipid Metabolism (DALM)”**  
New York, USA  
**Scientific sponsorship**
- September 2008    46. **International Symposium on “Dyslipidemia and Atherosclerosis”**  
Boca Chica, Dominican Republic  
**Scientific sponsorship**
- October 2010    47. **Symposium “Controversies on HDL as a therapeutic target”**  
Zurich, Switzerland
- June 3, 2011    48. **Symposium “Atrial fibrillation and stroke”**  
Marrakesh, Morocco
- March 25 – 29, 2012    49. **Satellite Symposium “Prevention of coronary heart disease and stroke” to XVI International Symposium on Atherosclerosis**  
Sydney, Australia
- June 1, 2013    50. **Symposium “Functional Foods and Cardiometabolic Diseases”**  
Naples, Italy

# International Task Force for Prevention of Cardiometabolic Diseases

dedicated to reducing cardiometabolic diseases world-wide

---



- Sep. 19, 2014      51. **Metabolic Syndrome: from Genetics to Clinical Aspects**  
Saint Petersburg, Russia
- Dec 11, 2015      52. **Translational Aspects in Lipids, Diabetes and Cardiovascular Prevention**  
**Expert Meeting in New York City, USA (planned, but cancelled)**
- May 20, 2016      53. **Risks and benefits of extremely low LDL cholesterol level**  
**Expert Meeting in Stockholm, Sweden**
- June 3, 2016      54. **Diabetes and atherosclerosis: New translational aspects.**  
**Symposium at a Symposium of the IAS (June 2-4, 2016)**  
Saint Petersburg, Russia **(planned, but cancelled)**
- June 16, 2017      55. **Diabetes, Coronary Artery Disease and Heart Failure**  
**Int. Conference in Aachen, Germany**
- June 08, 2018      56. **New Perspectives in Diabetes, Lipids, Coronary Plaque, and Heart**  
**Failure.**  
**Int. Conference in Aachen, Germany**
- Oct 18, 2018      57. **Diabetes and Heart Failure: Pathogenesis and new therapeutic**  
**Approaches.**  
**Expert Meeting in New York City, USA**
- Nov 08, 2019      58. **Cardiovascular Disease and Diabetes: Molecular Mechanisms and**  
**Clinical implications.**  
**Expert Meeting in Aachen, Germany**





## **The International Task Force for Prevention of Cardiometabolic Diseases was dissolved in 2021**

### **IMPRINT**

document created and completed as part of the archives  
for the  
**Assmann Foundation for Prevention**  
**Gronowskistraße 33**  
**48161 Münster**